AstraZeneca vaccine starting next month… Related stocks SK Chemicals, Gene Matrix, United Pharm, ABPro Bio?

AstraZeneca’s novel coronavirus infection (Corona 19) vaccine is being introduced from the beginning of next month, and attention is being drawn to related stocks.

AstraZeneca-related stocks are SK Chemicals, Gene Matrix, United Pharmaceuticals, and ABC Pro Bio.

As of 9:10 a.m. on the 25th, sk Chemicals is trading at 415,000 won, up 1.1% (4500 won), United Pharmaceuticals is trading at 53,800 won, up 4.26% (2200 won), and Gene Matrix is ​​trading at 2.92% (550 won). ) It is trading at 18,300 won, down, and Abprobio, down 1.99% (30 won), at 1475 won.

Following the international project’COVAX facility’ for joint purchase and distribution of vaccines, AstraZeneca vaccine is expected to be available next month. Like Kovex, the initial supply of 1 million people will be supplied first.

The AstraZeneca vaccine is expected to be given first to workers in high-risk medical institutions and to elderly people living in nursing hospitals and facilities. However, there is a possibility that the priorities will change as AstraZeneca vaccines have been pointed out that the results of vaccination for the elderly are limited.

Eun-mi Chun, a professor of respiratory medicine at Ewha Womans University Mokdong Hospital, said, “Pfizer, Modena vaccine has a lot of research on the elderly, but AstraZeneca vaccine does not have a final report on the elderly. “We need to clearly explain how the government will deal with this,” he said through Yonhap News.

The Ministry of Food and Drug Safety has received an application for a vaccine item license from the 4th and is currently reviewing non-clinical and clinical trial data, and plans to hold a meeting of the COVID-19 vaccine safety and effectiveness verification advisory group on the 31st.

Meanwhile, according to the quarantine authorities, the first quantity of vaccines (for 56 million people) secured by the government is the initial quantity of’Covax Facility’. The government signed a contract with Kovacs to supply 10 million vaccines, of which 50,000 are expected to arrive early next month.

The vaccines proposed by COVAX are the products of three companies, including AstraZeneca, Pfizer, and Sanofi-GlaxoMiscline, and are currently being reviewed most strongly by Pfizer.